Mucosal vaccines against respiratory syncytial virus

Current Opinion in Virology

Volumn 6, Issue 1, 2014, Pages 78-84

  Yang, Kejian ^a   Varga, Steven M ^b,c  

^a Biomedical Research Models Inc   (United States)

^b UNIVERSITY OF IOWA   (United States)

^c UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GUANINE NUCLEOTIDE BINDING PROTEIN; HYBRID PROTEIN; RESPIRATORY SYNCYTIAL VIRUS VACCINE; VIRUS PROTEIN; VIRUS ANTIGEN;

AMINO ACID SEQUENCE; ANTIGENICITY; ARTICLE; DRUG EFFICACY; DRUG SAFETY; HUMAN; MEMORY T LYMPHOCYTE; MUCOSAL IMMUNITY; NONHUMAN; POLYADENYLATION; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN DEGRADATION; PROTEIN STRUCTURE; RESPIRATORY SYNCYTIAL VIRUS INFECTION; T LYMPHOCYTE; ANIMAL; HUMAN RESPIRATORY SYNCYTIAL VIRUS; IMMUNIZATION; IMMUNOLOGY; MUCOSA; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; VIROLOGY;

ANIMALS; ANTIGENS, VIRAL; HUMANS; IMMUNITY, MUCOSAL; IMMUNIZATION; MUCOUS MEMBRANE; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUS VACCINES; RESPIRATORY SYNCYTIAL VIRUSES;

EID: 84903310024     PISSN: 18796257     EISSN: 18796265     Source Type: Journal    
DOI: 10.1016/j.coviro.2014.03.009     Document Type: Review

References (56)

1. R. Chanock, and L. Finberg Recovery from infants with respiratory illness of a virus related to chimpanzee coryza agent (CCA). II. Epidemiologic aspects of infection in infants and young children Am J Hyg 66 1957 291 300
2. R. Chanock, B. Roizman, and R. Myers Recovery from infants with respiratory illness of a virus related to chimpanzee coryza agent (CCA). I. Isolation, properties and characterization Am J Hyg 66 1957 281 290
3. B.S. Graham, and L.J. Anderson Challenges and opportunities for respiratory syncytial virus vaccines Curr Top Microbiol Immunol 372 2013 391 404
4. A.Z. Kapikian, R.H. Mitchell, R.M. Chanock, R.A. Shvedoff, and C.E. Stewart An epidemiologic study of altered clinical reactivity to respiratory syncytial (RS) virus infection in children previously vaccinated with an inactivated RS virus vaccine Am J Epidemiol 89 1969 405 421
5. H.W. Kim, J.G. Canchola, C.D. Brandt, G. Pyles, R.M. Chanock, K. Jensen, and R.H. Parrott Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine Am J Epidemiol 89 1969 422 434
6. B.R. Murphy, D.W. Alling, M.H. Snyder, E.E. Walsh, G.A. Prince, R.M. Chanock, V.G. Hemming, W.J. Rodriguez, H.W. Kim, and B.S. Graham et al. Effect of age and preexisting antibody on serum antibody response of infants and children to the F and G glycoproteins during respiratory syncytial virus infection J Clin Microbiol 24 1986 894 898
7. M.O. Blanken, M.M. Rovers, J.M. Molenaar, P.L. Winkler-Seinstra, A. Meijer, J.L. Kimpen, and L. Bont Respiratory syncytial virus and recurrent wheeze in healthy preterm infants New Engl J Med 368 2013 1791 1799
8. L.J. Anderson, P.R. Dormitzer, D.J. Nokes, R. Rappuoli, A. Roca, and B.S. Graham Strategic priorities for respiratory syncytial virus (RSV) vaccine development Vaccine 31 2013 B209 B215
9. L.J. Anderson Respiratory syncytial virus vaccine development Semin Immunol 25 2013 160 171
10. S.C. Brock, J.M. Heck, P.A. McGraw, and J.E. Crowe Jr. The transmembrane domain of the respiratory syncytial virus F protein is an orientation- independent apical plasma membrane sorting sequence J Virol 79 2005 12528 12535
11. G. Zimmer, L. Budz, and G. Herrler Proteolytic activation of respiratory syncytial virus fusion protein. Cleavage at two furin consensus sequences J Biol Chem 276 2001 31642 31650
12. G. Zimmer, K.K. Conzelmann, and G. Herrler Cleavage at the furin consensus sequence RAR/KR(109) and presence of the intervening peptide of the respiratory syncytial virus fusion protein are dispensable for virus replication in cell culture J Virol 76 2002 9218 9224
13. S. Chaiwatpongsakorn, R.F. Epand, P.L. Collins, R.M. Epand, and M.E. Peeples Soluble respiratory syncytial virus fusion protein in the fully cleaved, pretriggered state is triggered by exposure to low-molarity buffer J Virol 85 2011 3968 3977
14. J. Schlender, G. Zimmer, G. Herrler, and K.K. Conzelmann Respiratory syncytial virus (RSV) fusion protein subunit F2, not attachment protein G, determines the specificity of RSV infection J Virol 77 2003 4609 4616
15. N. Ternette, B. Tippler, K. Uberla, and T. Grunwald Immunogenicity and efficacy of codon optimized DNA vaccines encoding the F-protein of respiratory syncytial virus Vaccine 25 2007 7271 7279
16. J.L. Hurwitz Respiratory syncytial virus vaccine development Expert Rev Vaccines 10 2011 1415 1433
17. R. Rudraraju, B.G. Jones, R. Sealy, S.L. Surman, and J.L. Hurwitz Respiratory syncytial virus: current progress in vaccine development Viruses 5 2013 577 594
18. B.G. Jones, R.E. Sealy, R. Rudraraju, V.L. Traina-Dorge, B. Finneyfrock, A. Cook, T. Takimoto, A. Portner, and J.L. Hurwitz Sendai virus-based RSV vaccine protects African green monkeys from RSV infection Vaccine 30 2012 959 968
19. X. Zhan, J.L. Hurwitz, S. Krishnamurthy, T. Takimoto, K. Boyd, R.A. Scroggs, S. Surman, A. Portner, and K.S. Slobod Respiratory syncytial virus (RSV) fusion protein expressed by recombinant sendai virus elicits B-cell and T-cell responses in cotton rats and confers protection against RSV subtypes A and B Vaccine 25 2007 8782 8793
20. D. Martin, L.J. Calder, B. Garcia-Barreno, J.J. Skehel, and J.A. Melero Sequence elements of the fusion peptide of human respiratory syncytial virus fusion protein required for activity J Gen Virol 87 2006 1649 1658
21. K.A. Swanson, E.C. Settembre, C.A. Shaw, A.K. Dey, R. Rappuoli, C.W. Mandl, P.R. Dormitzer, and A. Carfi Structural basis for immunization with postfusion respiratory syncytial virus fusion F glycoprotein (RSV F) to elicit high neutralizing antibody titers Proc Natl Acad Sci U S A 108 2011 9619 9624
22. J.S. McLellan, Y. Yang, B.S. Graham, and P.D. Kwong Structure of respiratory syncytial virus fusion glycoprotein in the postfusion conformation reveals preservation of neutralizing epitopes J Virol 85 2011 7788 7796
23. L.J. Calder, L. Gonzalez-Reyes, B. Garcia-Barreno, S.A. Wharton, J.J. Skehel, D.C. Wiley, and J.A. Melero Electron microscopy of the human respiratory syncytial virus fusion protein and complexes that it forms with monoclonal antibodies Virology 271 2000 122 131
24. J.S. McLellan, M. Chen, M.G. Joyce, M. Sastry, G.B. Stewart-Jones, Y. Yang, B. Zhang, L. Chen, S. Srivatsan, A. Zheng, and T. Zhou et al. Structure-based design of a fusion glycoprotein vaccine for respiratory syncytial virus Science 342 2013 592 598
25. J.S. McLellan, M. Chen, S. Leung, K.W. Graepel, X. Du, Y. Yang, T. Zhou, U. Baxa, E. Yasuda, T. Beaumont, and A. Kumar et al. Structure of RSV fusion glycoprotein trimer bound to a prefusion-specific neutralizing antibody Science 340 2013 1113 1117
26. M. Magro, V. Mas, K. Chappell, M. Vazquez, O. Cano, D. Luque, M.C. Terron, J.A. Melero, and C. Palomo Neutralizing antibodies against the preactive form of respiratory syncytial virus fusion protein offer unique possibilities for clinical intervention Proc Natl Acad Sci U S A 109 2012 3089 3094
27. T. Zhou, L. Xu, B. Dey, A.J. Hessell, D. Van Ryk, S.H. Xiang, X. Yang, M.Y. Zhang, M.B. Zwick, J. Arthos, and D.R. Burton et al. Structural definition of a conserved neutralization epitope on HIV-1 gp120 Nature 445 2007 732 737
28. G. Smith, R. Raghunandan, Y. Wu, Y. Liu, M. Massare, M. Nathan, B. Zhou, H. Lu, S. Boddapati, J. Li, and D. Flyer et al. Respiratory syncytial virus fusion glycoprotein expressed in insect cells form protein nanoparticles that induce protective immunity in cotton rats PLoS ONE 7 2012 e50852
29. N. Lycke Recent progress in mucosal vaccine development: potential and limitations Nat Rev Immunol 12 2012 592 605
30. J. Holmgren, and A.M. Svennerholm Vaccines against mucosal infections Curr Opin Immunol 24 2012 343 353
31. J. Holmgren, and C. Czerkinsky Mucosal immunity and vaccines Nat Med 11 2005 S45 S53
32. M.A. Rose, S. Zielen, and U. Baumann Mucosal immunity and nasal influenza vaccination Expert Rev Vaccines 11 2012 595 607
33. T.G. Morrison, and E.E. Walsh Subunit and virus-like particle vaccine approaches for respiratory syncytial virus Curr Top Microbiol Immunol 372 2013 285 306
34. R.A. Karron, U.J. Buchholz, and P.L. Collins Live-attenuated respiratory syncytial virus vaccines Curr Top Microbiol Immunol 372 2013 259 284
35. G.M. Glenn, G. Smith, L. Fries, R. Raghunandan, H. Lu, B. Zhou, D.N. Thomas, S.P. Hickman, E. Kpamegan, S. Boddapati, and P.A. Piedra Safety and immunogenicity of a Sf9 insect cell-derived respiratory syncytial virus fusion protein nanoparticle vaccine Vaccine 31 2013 524 532
36. J.C. Blanco, M.S. Boukhvalova, L.M. Pletneva, K.A. Shirey, and S.N. Vogel A recombinant anchorless respiratory syncytial virus (RSV) fusion (F) protein/monophosphoryl lipid a (MPL) vaccine protects against RSV-induced replication and lung pathology Vaccine 2013
37. R. Singleton, N. Etchart, S. Hou, and L. Hyland Inability to evoke a long-lasting protective immune response to respiratory syncytial virus infection in mice correlates with ineffective nasal antibody responses J Virol 77 2003 11303 11311
38. E.E. Walsh, and A.R. Falsey Humoral and mucosal immunity in protection from natural respiratory syncytial virus infection in adults J Infect Dis 190 2004 373 378
39. A. Cherukuri, K. Patton, R.A. Gasser Jr., F. Zuo, J. Woo, M.T. Esser, and R.S. Tang Adults 65 years old and older have reduced numbers of functional memory T cells to respiratory syncytial virus fusion protein Clin Vaccine Immunol 20 2013 239 247
40. A.R. Falsey, E.E. Walsh, J. Capellan, S. Gravenstein, M. Zambon, E. Yau, G.J. Gorse, R. Edelman, F.G. Hayden, J.E. McElhaney, and K.M. Neuzil et al. Comparison of the safety and immunogenicity of 2 respiratory syncytial virus (RSV) vaccines - nonadjuvanted vaccine or vaccine adjuvanted with alum - given concomitantly with influenza vaccine to high-risk elderly individuals J Infect Dis 198 2008 1317 1326
41. J.R. Groothuis, S.J. King, D.A. Hogerman, P.R. Paradiso, and E.A. Simoes Safety and immunogenicity of a purified f protein respiratory syncytial virus (PFP-2) vaccine in seropositive children with bronchopulmonary dysplasia J Infect Dis 177 1998 467 469
42. T. Grunwald, M. Tenbusch, R. Schulte, K. Raue, H. Wolf, D. Hannaman, R.L. de Swart, K. Uberla, and C. Stahl-Hennig Novel vaccine regimen elicits strong airway immune responses and control of respiratory syncytial virus in non-human primates J Virol 2014 [Epub ahead of print]
43. A. McMichael, L.J. Picker, J.P. Moore, and D.R. Burton Another HIV vaccine failure: where to next? Nat Med 19 2013 1576 1577
44. R.S. Tirabassi, C.I. Ace, T. Levchenko, V.P. Torchilin, L.K. Selin, S. Nie, D.L. Guberski, and K. Yang A mucosal vaccination approach for herpes simplex virus type 2 Vaccine 29 2011 1090 1098
45. K. Yang, B.J. Whalen, R.S. Tirabassi, L.K. Selin, T.S. Levchenko, V.P. Torchilin, E.H. Kislauskis, and D.L. Guberski A DNA vaccine prime followed by a liposome-encapsulated protein boost confers enhanced mucosal immune responses and protection J Immunol 180 2008 6159 6167
46. M. Vajdy, B. Baudner, G. Del Giudice, and D. O'Hagan A vaccination strategy to enhance mucosal and systemic antibody and T cell responses against influenza Clin Immunol 123 2007 166 175
47. J.B. Domachowske, and H.F. Rosenberg Respiratory syncytial virus infection: immune response, immunopathogenesis, and treatment Clin Microbiol Rev 12 1999 298 309
48. M. Vaine, S. Wang, Q. Liu, J. Arthos, D. Montefiori, P. Goepfert, M.J. McElrath, and S. Lu Profiles of human serum antibody responses elicited by three leading HIV vaccines focusing on the induction of Env-specific antibodies PLoS ONE 5 2010 e13916
49. M. Vaine, S. Wang, A. Hackett, J. Arthos, and S. Lu Antibody responses elicited through homologous or heterologous prime-boost DNA and protein vaccinations differ in functional activity and avidity Vaccine 28 2010 2999 3007
50. M. Vaine, S. Wang, E.T. Crooks, P. Jiang, D.C. Montefiori, J. Binley, and S. Lu Improved induction of antibodies against key neutralizing epitopes by human immunodeficiency virus type 1 gp120 DNA prime-protein boost vaccination compared to gp120 protein-only vaccination J Virol 82 2008 7369 7378
51. S. Wang, C. Parker, J. Taaffe, A. Solorzano, A. Garcia-Sastre, and S. Lu Heterologous HA DNA vaccine prime - inactivated influenza vaccine boost is more effective than using DNA or inactivated vaccine alone in eliciting antibody responses against H1 or H3 serotype influenza viruses Vaccine 26 2008 3626 3633
52. J.H. Schickli, F. Dubovsky, and R.S. Tang Challenges in developing a pediatric RSV vaccine Hum Vaccines 5 2009 582 591
53. H. Mok, S. Lee, T.J. Utley, B.E. Shepherd, V.V. Polosukhin, M.L. Collier, N.L. Davis, R.E. Johnston, and J.E. Crowe Jr. Venezuelan equine encephalitis virus replicon particles encoding respiratory syncytial virus surface glycoproteins induce protective mucosal responses in mice and cotton rats J Virol 81 2007 13710 13722
54. M. Shafique, J. Wilschut, and A. de Haan Induction of mucosal and systemic immunity against respiratory syncytial virus by inactivated virus supplemented with TLR9 and NOD2 ligands Vaccine 30 2012 597 606
55. A. Rigter, I. Widjaja, H. Versantvoort, F.E. Coenjaerts, M. van Roosmalen, K. Leenhouts, P.J. Rottier, B.J. Haijema, and C.A. de Haan A protective and safe intranasal RSV vaccine based on a recombinant prefusion-like form of the F protein bound to bacterium-like particles PLoS ONE 8 2013 e71072
56. Cyr S.L.,Jones T.,Stoica-Popescu I.,Brewer A.,Chabot S.,Lussier M.,Burt D.,Ward B.J.,Intranasal proteosome-based respiratory syncytial virus (RSV) vaccines protect BALB/c mice against challenge without eosinophilia or enhanced pathology Vaccine 2007 25 5378-5389